Supreme Court to take drug pricing case

Dec. 8, 2012 at 2:56 PM

WASHINGTON, Dec. 8 (UPI) -- The U.S. Supreme Court said it will rule in a case involving payments by pharmaceutical companies to rivals in return for delaying sales of generic drugs.

The Federal Trade Commission says the so-called pay-for-delay deals violate antitrust law, preserve monopolies and artificially jack up prices, the Los Angeles Times said Saturday.

The commission said 28 such agreements cost consumers and taxpayers at least $3.5 billion in 2011, the newspaper reported.

"When drug companies agree not to compete, consumers lose," FTC Chairman Jon Leibowitz said.

Federal courts have upheld such deals in a number of cases, finding they constitute settlements of patent disputes.

The Supreme Court said Friday it would consider a case involving an agreement in which Solvay Pharmaceuticals Inc., which makes the testosterone booster AndroGel, agreed to pay Watson Pharmaceuticals Inc. more than $19 million a year in return for Watson's agreement to hold a competitive drug off the market until 2015.

Related UPI Stories
Latest Headlines
Trending Stories
Vatican: Pope's meeting with Kim Davis not a show of support
Potential male contraceptive found in study with mice
Cancer and height are linked, new study shows
Hacker may have exposed data of 15 million T-Mobile customers
Education Secretary Arne Duncan to step down in December